🔴 Intellia Therapeutics is trading 5% down amid a 2.08% drop in biotech stocks

Intellia Therapeutics is trading at $10.59, down 5.11%, amid a broader risk-off session and weakness in biotech stocks.

• Available reporting surfaced no clear company-specific announcement explaining the October 23 decline; a new chief medical officer appointment was mentioned but not linked to the move.
• Biotech stocks fell 2.08%, with geopolitical concerns and market weakness weighing on sentiment.
• Recent company coverage highlighted FDA priority review for lonvo-z, with a decision expected in March 2027.